3rd Quarter - Report

TEVA PHARMACEUTICALS USA, INC. for TEVA PHARMACEUTICALS USA INC

Firm
Client
Income
—
Expenses
$810,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market

Foreign entity interest: Teva Pharmaceuticals Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, Inc. has an indirect interest in the issues listed above.

LobbyistCovered position, as disclosed
SUSIE AHN —
DEBRA BARRETT —
GRANT ERDEL —
ROBERT FALB —
TERRI STEWART —

Contacted: Food & Drug Administration (FDA); Patent & Trademark Office (PTO); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; SENATE; White House Office

Bills named: S. 504 (113th), S. 214 (113th)

Pharmacy PHA

Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives, Plan B; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act.

Foreign entity interest: Teva Pharmaceuticals Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, Inc. has an indirect interest in the issues listed above.

LobbyistCovered position, as disclosed
SUSIE AHN —
DEBRA BARRETT —
GRANT ERDEL —
ROBERT FALB —
TERRI STEWART —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Patent & Trademark Office (PTO); U.S. Trade Representative (USTR); White House Office; Food & Drug Administration (FDA)

Bills named: S. 959 (113th), S.Con.Res. 8 (113th), H.R. 486 (113th), H.R. 1919 (113th)

Tariff (miscellaneous tariff bills) TAR

Temporarily suspend the duty on S-(2-benzothiazolyl)-2-(2-amino-thiazol-4-yl)-2-acetoxyimino thiocetate (Thioester).

Foreign entity interest: Teva Pharmaceuticals, Ltd., as an indirect parent of Teva Pharmaceuticals USA, Inc., has an indirect interest in the issue(s) listed above.

LobbyistCovered position, as disclosed
DEBRA BARRETT —
GRANT ERDEL —
TERRI STEWART —

Contacted: Patent & Trademark Office (PTO); Food & Drug Administration (FDA); White House Office; HOUSE OF REPRESENTATIVES; SENATE; U.S. Trade Representative (USTR)

Trade (domestic/foreign) TRD

Trans-Pacific Partnership Trade Agreement

Foreign entity interest: Teva Pharmaceuticals Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, Inc. has an indirect interest in the issues listed above.

LobbyistCovered position, as disclosed
DEBRA BARRETT —
GRANT ERDEL —
TERRI STEWART —

Contacted: Patent & Trademark Office (PTO); U.S. Trade Representative (USTR); SENATE; White House Office; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.